

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source	Page Number	Errata Post	Errata Official	Target Errata	Target Online	Description
		Publication		Date	Date	Print Publication	Fix Publication	
TIMOLOL	ADDITIONAL R	USP40–NF35	6481	ascending 26-Jan-2018	1-Feb-2018	USP42–NF37	Second	Line 3 of USP

Monograph Title Section		Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MALEATE TABLETS	EQUIREMENT S/USP Reference Standards <11>						<i>Supplement to USP41–NF36</i>	Timolol Related Compound D RS: Change $C_6H_9N_7O_4S$ to:
								$C_6H_9N_3O_2S$
ECHINACEA A NGUSTIFOLIA	IDENTIFICATIO N	USP40–NF35	6923	26-Jan-2018	1-Feb-2018	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	Line 5 of A. <i>Thin-Layer Chromatography/Presence of echinacoside and dicaffeoylquinic acid/System suitability: Change Standard solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to:</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED ECHINACEA A N NGUSTIFOLIA	IDENTIFICATIO USP40–NF35	6926	26-Jan-2018	1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	<i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND Line 3 of C.: Change <i>Standard solution B</i>; to: <i>Standard solution C</i>; Line 5 of A. <i>Thin-Layer Chromatography/Presence of echinacoside and dicaffeoylquinic acid/System suitability:</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Change <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED IDENTIFICATION ECHINACEA AN GUSTIFOLIA EXTRACT	USP40–NF35	6928	26-Jan-2018	1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	Line 3 of C.: Change <i>Standard solution B</i> , to: <i>Standard solution C</i> , Line 5 of A. <i>Thin-Layer Chromatography/Presence of echinacoside and dicaffeoylquinic acid/System suitability:</i> Change <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECHINACEA PALLIDA	IDENTIFICATIO N	USP40–NF35	6931	26-Jan-2018	1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND Line 3 of C.: Change <i>Standard solution B</i>; to: <i>Standard solution C</i>; Line 5 of A. <i>Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid/System</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>suitability:</i> Change <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED ECHINACEA PALLIDA	IDENTIFICATION	USP40–NF35	6933	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	AND Lines 3 and 6 of C.: Change <i>Standard solution B</i>, to: <i>Standard solution C</i>, AND Change <i>Standard solution C</i>) to: <i>Standard solution D</i>) Line 5 of A. <i>Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid/System suitability:</i> Change <i>Standard solution B</i> shows two major blue bands at about the middle of

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND Lines 3 and 6 of C.: Change <i>Standard solution B</i>, to: <i>Standard solution C</i>,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED ECHINACEA PALLIDA EXTRACT	IDENTIFICATION	USP40–NF35	6935	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	AND Change <i>Standard solution C)</i> to: <i>Standard solution D)</i> Line 5 of A. <i>Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid/System suitability:</i> Change <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECHINACEA	IDENTIFICATIO	USP40–NF35	6937	26-Jan-2018	1-Feb-2018	USP42–NF37	Second	to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND Lines 3 and 6 of C.: Change <i>Standard solution B</i>, to: <i>Standard solution C</i>, AND Change <i>Standard solution C</i>) to: <i>Standard solution D</i>) Line 3 of A.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PURPUREA N AERIAL PARTS						Supplement to USP41–NF36	Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacinic acid/Thin-Layer Chromatography/ System suitability: Change Standard solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) that are clearly separated, to: Standard solution B shows two major blue bands at about the middle of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECHINACEA PURPUREA ROOT	IDENTIFICATION	USP40–NF35	6940	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, Line 3 of A. <i>Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacinate/ System suitability: Change Standard solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F)</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED ECHINACEA PURPUREA	IDENTIFICATION	USP40–NF35	6942	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	^{F)} that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, Line 3 of A. <i>Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacinate/ System suitability: Change Standard</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED ECHINACEA PURPUREA	IDENTIFICATION	USP40–NF35	6944	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	<i>solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, Line 3 of A. <i>Thin-Layer Chromatography/Pre</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EXTRACT							sence of chicoric acid and absence of ec hinac oside/System suitability: Change Standard solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: Standard solution B shows two major blue bands at about the middle of the chromatogram

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHENYTOIN ORAL SUSPENSION	PERFORMANCE TESTS/ <i>Dissolution</i> <711>	USP41–NF36	3286	26-Jan-2018		1-Feb-2018	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, In the <i>Analysis</i> : Change C_S = concentration of USP Phenytoin RS in the <i>Standard solution</i> to: C_S = concentration of USP Phenytoin RS in the <i>Standard solution</i> (mg/mL)
ECHINACEA SPECIES DRY EXTRACT CAPSULES	IDENTIFICATION	USP41–NF36	4590	26-Jan-2018		1-Feb-2018	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	Line 4 of A. <i>HPTLC for Articles of Botanical Origin</i> <203>/For Capsules containing <i>Echinacea angustifolia</i> Dry

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECHINACEA	IDENTIFICATIO	USP41–NF36	4592	26-Jan-2018		1-Feb-2018	USP42–NF37	Second	<i>Extract/System suitability:</i> Change <i>Standard solution B</i> shows two major blue bands at about the middle section due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle section due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, Line 4 of A.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SPECIES DRY N EXTRACT TABLETS						Supplement to USP41–NF36	HPTLC for Articles of Botanical Origin <203>/For Tablets containing Echinacea angustifolia Dry Extract/System suitability: Change Standard solution B shows two major blue bands at about the middle section due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: Standard solution B shows two major blue bands at about the middle

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECHINACEA SPECIES POWDER CAPSULES	IDENTIFICATION	USP41–NF36	4595	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	section due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, Line 4 of A. HPTLC for Articles of Botanical Origin <203>/For Capsules containing <i>Echinacea angustifolia</i> powder prepared from dried rhizome and roots/System suitability: Change Standard solution B shows two major blue bands at about the middle section due to caftaric acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESZOPICLONE ADDITIONAL R TABLETS	EQUIREMENT S/USP Reference Standards <11>	Revision Bulletin (Official August 01, 2017)	Online	26-Jan-2018		1-Feb-2018	USP42–NF37	Second Supplement to USP41–NF36	(lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: <i>Standard solution B</i> shows two major blue bands at about the middle section due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, Line 2 of USP Eszopiclone Related Compound A RS: Change 6-(5-Chloropyridin-2-yl)-7-oxo-6, 7-di hydro-5H -pyr rolo[3,4 -b]pyrazin-5-yl 4

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 to: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrido[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrido[3,4-b]pyrazin-5-yl 4-methylpiperazi

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
QUETIAPINE EXTENDED-RELEASE TABLETS	IM PURITIES/Organic Impurities	Revision Bulletin (Official November 01, 2017)	Online	26-Jan-2018	1-Feb-2018	USP42–NF37 Second Supplement to USP41–NF36	ne-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1). C ₁₇ H ₁₇ ClN ₆ O ₄ · C ₇ H ₅ ClO 561.38 Footnote a of Table 5: Change total impurities. to: total degradation products. AND Footnote b: Change total impurities. to: total degradation products. Line 3 of System suitability: Change Table 4 to: Table 13 Line 2 of USP Timolol Related
NIACIN EXTENDED-RELEASE TABLETS	ASSAY/Procedure	Revision Bulletin (Official January 01, 2018)	Online	26-Jan-2018	1-Feb-2018	USP42–NF37 Second Supplement to USP41–NF36	
TIMOLOL MALEATE	ADDITIONAL REQUIREMENT	First Supplement to	8416	26-Jan-2018	1-Feb-2018	USP42–NF37 Second Supplement to	

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<i>SIUSP Reference Standards <11></i>	<i>USP40–NF35</i>					<i>USP41–NF36</i>	Compound A RS: Change (<i>R</i>)-1-(<i>tert</i>-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol. C₁₃H₂₄N₄O₃S 316.42 to: (<i>R</i>)-1-(<i>tert</i>-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol maleate. C₁₃H₂₄N₄O₃S · C₄H₄O₄ 432.49 AND Line 2 of USP Timolol Related Compound C RS: Change <i>N</i>-(<i>tert</i>-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							$C_{19}H_{31}N_7O_4S_2$ 485.19 to: <i>N</i>-(<i>tert</i>-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine maleate. $C_{19}H_{31}N_7O_4S_2$? $C_4H_4O_4$ 601.69 AND Line 3 of USP Timolol Related Compound D RS: Change $C_6H_9N_7O_4S$ to: $C_6H_9N_3O_2S$ AND Line 2 of USP Timolol Related Compound E RS: Change (<i>S</i>)-3-(<i>tert</i>-Butylamino)-1-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-yl hydrogen maleate.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									$C_{17}H_{26}N_4O_6S$ 414.48 to: (S,Z)-4-({1-(<i>tert</i> -Butylamino)-3-[(4-morpholino-1 ,2,5-thiadiazol-3 -yl)oxy]propan-2 -yl}oxy)-4-oxobu t-2-enoic acid maleate salt (1:1) $C_{17}H_{26}N_4O_6S$? $C_4H_4O_4$ 530.55 Line 2 of 0.06 M Phosphoric Acid TS: Change volumetric flask to: 1000-mL volumetric flask Line 2 of Chromatographi c system/ Developing solvent system:Change acetic acid
REAGENTS, INDICATORS AND SOLUTIONS	<i>Solutions/Test Solutions/3. Solutions Prepared Fresh</i>	USP40–NF35	2419	29-Dec-2017		1-Jan-2018	USP42–NF37	Second Supplement to USP41–NF36	$C_{17}H_{26}N_4O_6S$? $C_4H_4O_4$ 530.55 Line 2 of 0.06 M Phosphoric Acid TS: Change volumetric flask to: 1000-mL volumetric flask Line 2 of Chromatographi c system/ Developing solvent system:Change acetic acid
VALERIAN	IDENTIFICATIO N/C. <i>Thin-Layer Chromatograph y</i>	USP40–NF35	7238	29-Dec-2017		1-Jan-2018	USP42–NF37	Second Supplement to USP41–NF36	$C_{17}H_{26}N_4O_6S$? $C_4H_4O_4$ 530.55 Line 2 of 0.06 M Phosphoric Acid TS: Change volumetric flask to: 1000-mL volumetric flask Line 2 of Chromatographi c system/ Developing solvent system:Change acetic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED VALERIAN	IDENTIFICATION/C. Thin-Layer Chromatography	USP40–NF35	7240	29-Dec-2017		1-Jan-2018	USP42–NF37	Second Supplement to USP41–NF36	to: glacial acetic acid AND Line 2 of Chromatography c system/ Derivatization reagent B: Change acetic acid to: glacial acetic acid Line 2 of Chromatography c system/ Developing solvent system:Change acetic acid to: glacial acetic acid AND Line 2 of Chromatography

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED VALERIAN EXTRACT	IDENTIFICATION N/A. <i>Thin-Layer Chromatography</i>	USP40–NF35	7241	29-Dec-2017		1-Jan-2018	USP42–NF37	Second Supplement to USP41–NF36	c system/ Derivatization reagent B: Change acetic acid to: glacial acetic acid Line 2 of Chromatographi c system/ Developing solvent system:Change acetic acid to: glacial acetic acid AND Line 2 of Chromatographi c system/ Derivatization reagent B: Change acetic acid to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VALERIAN TINCTURE	IDENTIFICATION N/A. <i>Thin-Layer Chromatography</i>	USP40–NF35	7243	29-Dec-2017	1-Jan-2018	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	glacial acetic acid Line 2 of <i>Chromatography system/ Developing solvent system</i> :Change acetic acid to: glacial acetic acid AND Line 2 of <i>Chromatography system/ Derivatization reagent B</i> : Change acetic acid to: glacial acetic acid
VALERIAN TABLETS	IDENTIFICATION N/A. <i>Thin-Layer Chromatography</i>	USP40–NF35	7244	29-Dec-2017	1-Jan-2018	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	Line 2 of <i>Chromatography system/ Developing</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CLINDAMYCIN IM PHOSPHATE	PUR ITIES/Organic Impurities/Table 2	Revision Bulletin (Official May 01, 2017)	Online	29-Dec-2017		1-Jan-2018	USP42–NF37	Second Supplement to USP41–NF36	solvent system:Change acetic acid to: glacial acetic acid AND Line 2 of Chromatographi c system/ Derivatization reagent B: Change aceticacid to: glacial acetic acid Footnote e and f: Change ^e Methyl 7-chloro-6,7,8-trideoxy-6-[(2S,4R)-1-methyl-4-ethylpyrrolidine-2-carboxamido]-1-thio-L-threo-?-D-galacto-octopyranoside

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							3-phosphate. ^f Methyl 7-chloro-6,7,8-trideoxy-6-[(2 <i>S</i> ,4 <i>R</i>)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-D- <i>threo</i> -?-D- <i>galacto</i> -octopyranoside . to: ^e Methyl 7-chloro-6,7,8-trideoxy-6-[(2 <i>S</i> ,4 <i>R</i>)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-L- <i>threo</i> -?-D- <i>galacto</i> -octopyranoside 3-phosphate. ^f Methyl 7-chloro-6,7,8-trideoxy-6-[(2 <i>S</i> ,4 <i>R</i>)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-L-

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>threo</i> -?-D-galacto-octopyranoside
OLMESARTAN ASSAY/ MEDOXOMIL TABLETS	<i>Chromatographic system</i>	<i>Revision Bulletin (Official August 01, 2017)</i>	Online	29-Dec-2017	1-Jan-2018	<i>USP42–NF37</i>	<i>Second Supplement to USP41–NF36</i> Line 1 of <i>Detector:</i> Change <i>Identification B</i> to: <i>Identification A</i>
CHLOROQUIN IM E PHOSPHATE PUR ITIES/ <i>Organic Impurities</i>		<i>USP40–NF35</i>	3377	17-Nov-2017	1-Dec-2017	<i>USP42–NF37</i>	<i>Second Supplement to USP41–NF36</i> Line 3 of <i>Analysis:</i> Change Calculate the percentage of each specified impurity to: Calculate the percentage of each specified impurity, other than chloroquine related compound G, AND In <i>Analysis</i> /second equation/variable definition list:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORPHENIRAMINE MALEATE	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP40–NF35	3385	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Change r_U=peak response of chloroquine <i>N</i>-oxide or any other impurity from the <i>Sample solution</i> r_U=peak response of chloroquine related compound G or any other impurity from the <i>Sample solution</i> Line 2 of USP C hlorpheniramine Related Compound C RS: Change 3-(4-Chlorophenyl)-<i>N</i>-methyl-3-(pyridin-2-yl)propan-1-amine. $C_{15}H_{17}ClN_2$ 260.76 to: 3-(4-Chlorophe

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CILOSTAZOL	USP Reference standards <11>	USP40–NF35 3418	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	nyl)-N -methyl-3-(pyridi n-2-yl)propan-1- amine maleate. $C_{15}H_{17}ClN_2 \cdot$ $C_4H_4O_4$ 376.83 Line 2 of USP Cilostazol Related Compound C RS: Change 1-(4-(5-Cyclohe xyl-1H -tetrazol-1-yl)bu tyl)-6-(4-(1-cycl ohexyl- 1H -tetrazol-5-yl)bu toxy)-3,4-dihydr oq uinoli n-2(1H)-one. $C_{31}H_{43}N_9O_3$ 589.73 to: 1-(4-(1-Cyclohe xyl-1H -tetrazol-5-yl)bu tyl)-6-(4-(1-cycl ohexyl- 1H

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DEXCHLORPH ENIRAMINE MALEATE	ADDITIONAL R EQUIREMENT S/USP Reference Standards <11>	USP40–NF35	3685	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	-tetrazol-5-yl)bu toxy)-3,4-dihydr oq uinoli n-2(1 <i>H</i>)-one. C ₃₁ H ₄₅ N ₉ O ₂ 575.75 Line 2 of USP C hlorpheniramine Related Compound C RS: Change 3-(4-Chlorophe nyl- <i>N</i> -methyl-3-(pyridi n-2-yl)propan-1- amine. C ₁₅ H ₁₇ ClN ₂ 260.76 to: 3-(4-Chlorophe nyl)- <i>N</i> -methyl-3-(pyridi n-2-yl)propan-1- amine maleate. C ₁₅ H ₁₇ ClN ₂ · C ₄ H ₄ O ₄ 376.83
DONEPEZIL H YDROCHLORI DE	IM PUR ITIES/Organic Impurities,	USP40–NF35	3859	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Footnote b of Table 3: Change (E

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<i>Procedure 2</i>							)-4-[(5,6-Dimethoxy-1-oxo-1 <i>H</i> -inden-2-yl)methyl]pyridine 1-oxide. to: (<i>E</i>)-4-[(5,6-Dimethoxy-1-oxo-1,3-dihydro-2 <i>H</i> -inden-2-ylidene)methyl]pyridine 1-oxide.
GLUTARAL CO ASSAY/ NCENTRATE <i>Procedure</i>	USP40–NF35	4414	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 7 of <i>Analysis</i> : Change Add a weighed quantity of Concentrate containing 1.2 g of glutaral by means of a suitable weighing pipet. to: Add 1.2 g of Glutaral Concentrate.
HYDROXYZINE ASSAY/ HYDROCHLOR <i>Procedure</i>	USP40–NF35	4539	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to	Line 2 of <i>Solution B</i> :

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE						USP41–NF36	Change (0.5: 99.5) to: (0.05: 99.95)
HYDROXYZINE ASSAY/ HYDROCHLORIDE TABLETS	USP40–NF35	4542	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 2 of Solution B: Change (0.5: 99.5) to: (0.05: 99.95)
IRINOTECAN HADDITIONAL REQUIREMENT HYDROCHLORIDE Reference Standards <11>	USP40–NF35	4676	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 2 of USP Irinotecan Related Compound C RS: Change (S)-9-[(1,4-bis(piperidin-1-yl)-4-methyl-11-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dihydro-1H-pyrano[3,4-b]quinoline hydrochloride. to: 11-Ethyl-4-hydr

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							oxy-4-methyl-3, 14-dioxo-3,4,12, <i>H</i> -pyrano[3?,4?:6, <i>b</i>]quinolin-9-yl (1,4?-bipiperidin e)-1?-carboxylat e hydrochloride. In <i>Acid stage/</i> <i>Analysis/</i> <i>s/variable</i> definition list: Change V = volume of <i>Medium</i> , 750 mL to: V = volume of <i>Acid stage medium</i> , 750 mL AND In <i>Buffer stage/</i>
MYCOPHENOL PERFORMANC IC ACID DELAYE ED-RELEASE TESTS/ TABLETS <i>Dissolution</i> <711>	USP40–NF35	5257	17-Nov-2017	1-Dec-2017	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>Analysis/variable definition list:</i> Change <i>V = volume of Medium, 1000 mL</i> to: <i>V = volume of Buffer stage medium, 1000 mL</i>
MYCOPHENOLIM IC ACID DELAYPUR ED-RELEASE ITIES/ <i>Organic</i> TABLETS <i>Impurities</i>	USP40–NF35	5257	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Change <i>Mobile phase, Standard solution, Sample solution, and Chromatographic system:</i> to: <i>Mobile phase, Diluent, Standard solution, Sample solution, and Chromatographic system:</i>
PILOCARPINE ASSAY/ HYDROCHLOR <i>Procedure</i>	USP40–NF35	5706	17-Nov-2017	1-Dec-2017	USP42–NF37	Second Supplement to	Line 2 of <i>Standard</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE OPHTHALMIC SOLUTION								USP41–NF36	solution: Change water to: methanol
VERAPAMIL H YDROCHLORI DE EXTENDED-TESTS/ RELEASE TABLETS	PERFORMANC E Dissolution <711>	USP40–NF35	6680	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Row 5 of column 2 of Table 9: Change 4 to: 5
CALCIUM STEARATE	IDENTIFICATIO N	USP40–NF35	7557	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 3 of B.: Change obtained in the Assay. to: obtained in the Assay for Content of Stearic Acid and Palmitic Acid.
VISUAL INSPECTION OF INJECTIONS	2. BACKGROU ND/2.2 Patient Risk	First Supplement to USP40–NF35	8099	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 6 of paragraph 3: Change 109 particles/kg to: 10 ⁹ particles/kg
VISUAL INSPECTION	4. INSPECTION LI	First Supplement to	8099	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to	Line 5 of paragraph 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OF INJECTIONS	FE-CYCLE/4.2 <i>Prevention of Particulates</i>	USP40–NF35						USP41–NF36	<i>Robust Design During Development: Change lamellae (46,47) to: lamellae as discussed in Evaluation of the Inner Surface Durability of Glass Containers <1660> and by the FDA (45) AND Line 2 of paragraph 4 of Robust Design During Development: Change (ICH)-relevant trials. to: (ICH)-relevant trials (46).</i>
HYDROXYZINE ASSAY/ HYDROCHLORIDE ORAL	<i>Procedure</i>	<i>First Supplement to USP40–NF35</i>	8299	17-Nov-2017		1-Dec-2017	USP42–NF37	<i>Second Supplement to USP41–NF36</i>	<i>Line 2 of Solution B: Change</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOLUTION									(0.5: 99.5) to: (0.05: 99.95)
ALMOTRIPTAN TABLETS	ADDITIONAL R EQUIREMENT S/USP Reference Standards <11>	<i>Second Supplement to USP40–NF35</i>	8708	17-Nov-2017		1-Dec-2017	<i>USP42–NF37</i>	<i>Second Supplement to USP41–NF36</i>	Line 4 of USP Almotriptan Related Compound B RS: Change $C_{15}H_{22}N_3O_2S$ to: $C_{15}H_{21}N_3O_2S$ AND Line 2 of USP Almotriptan Related Compound D RS: Change 1-[(3-[2-(Dimethylamino)ethyl]indol-5-yl)methyl)sulfonyl]pyrrolidine <i>N</i> -oxide. $C_{17}H_{25}N_3O_3S$ 351.46 to: 1-[(3-[2-(Dimethylamino)ethyl]indol-5-yl)methyl)sulfonyl]pyrrolidine <i>N</i> -oxide hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIVALPROEX ASSAY/ SODIUM EXTENDED- RELEASE TABLETS	Procedure	Second Supplement to USP40–NF35	8752	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	C ₁₇ H ₂₅ N ₃ O ₃ S · HCl 387.92 Line 2 of Mobile phase: Change Adjust with phosphoric acid to a pH of 5.0. to: Adjust with diluted sodium hydroxide or phosphoric acid to a pH of 5.0.
FLUVOXAMINE MALEATE	ASSAY/ Procedure	Second Supplement to USP40–NF35	8797	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 2 of Solution A: Change 1 g/L to: 1.1 g/L
SODIUM LAURYL SULFATE	IDENTIFICATION	Second Supplement to USP40–NF35	8946	17-Nov-2017		1-Dec-2017	USP42–NF37	Second Supplement to USP41–NF36	Line 1 of A.: Change Infrared Absorption <197K> or <197A> to: ?A. Infrared Absorption <197K> or <197A>?
HAZARDOUS 5. FACILITIES		First	Online	17-Nov-2017		1-Dec-2017	USP42–NF37	Second	Line 5 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DRUGS—HANDLING IN HEALTHCARE SETTINGS	DAND ENGINEERING CONTROLS/5.4 <i>Containment Supplemental Engineering Controls</i>	<i>Supplement to USP40–NF35</i>						<i>Supplement to USP41–NF36</i>	paragraph 1: Change containment reduction. to: contamination reduction.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	7. PERSONAL PROTECTIVE EQUIPMENT	<i>First Supplement to USP40–NF35</i>	Online	17-Nov-2017		1-Dec-2017	<i>USP42–NF37</i>	<i>Second Supplement to USP41–NF36</i>	Line 2 of paragraph 2: Change antineoplastic HDs. to: injectable antineoplastic HDs.

Pagination

- [First page « First](#)
- [Previous page < Previous](#)
- ...
- [Page 17](#)
- [Page 18](#)
- [Page 19](#)
- [Page 20](#)
- [Page 21](#)
- [Page 22](#)
- [Page 23](#)
- [Page 24](#)
- [Page 25](#)

-
- ...
 - [_Next page Next >](#)
 - [_Last page Last »](#)